Telemark Asset Management LLC Reduces Holdings in GeneDx Holdings Corp. $WGS

Telemark Asset Management LLC decreased its position in shares of GeneDx Holdings Corp. (NASDAQ:WGS) by 16.7% during the 4th quarter, HoldingsChannel.com reports. The firm owned 100,000 shares of the company’s stock after selling 20,000 shares during the quarter. GeneDx makes up approximately 1.3% of Telemark Asset Management LLC’s portfolio, making the stock its 28th largest holding. Telemark Asset Management LLC’s holdings in GeneDx were worth $13,006,000 as of its most recent filing with the SEC.

Several other hedge funds have also made changes to their positions in the business. Ramirez Asset Management Inc. acquired a new stake in shares of GeneDx during the fourth quarter worth about $33,000. Westfield Capital Management Co. LP boosted its stake in shares of GeneDx by 87.1% during the fourth quarter. Westfield Capital Management Co. LP now owns 1,018,261 shares of the company’s stock worth $132,435,000 after buying an additional 474,167 shares during the period. TD Asset Management Inc boosted its stake in shares of GeneDx by 10.7% during the fourth quarter. TD Asset Management Inc now owns 37,016 shares of the company’s stock worth $4,814,000 after buying an additional 3,584 shares during the period. Bank of New York Mellon Corp boosted its stake in shares of GeneDx by 39.8% during the fourth quarter. Bank of New York Mellon Corp now owns 227,586 shares of the company’s stock worth $29,600,000 after buying an additional 64,837 shares during the period. Finally, Goldman Sachs Group Inc. boosted its stake in shares of GeneDx by 4.5% during the fourth quarter. Goldman Sachs Group Inc. now owns 1,220,502 shares of the company’s stock worth $158,738,000 after buying an additional 52,322 shares during the period. Institutional investors and hedge funds own 61.72% of the company’s stock.

GeneDx Trading Down 7.2%

NASDAQ WGS opened at $52.21 on Friday. The stock has a market capitalization of $1.55 billion, a P/E ratio of -19.48 and a beta of 1.96. GeneDx Holdings Corp. has a 52-week low of $32.21 and a 52-week high of $170.87. The firm has a 50-day moving average price of $55.44 and a 200 day moving average price of $92.90. The company has a quick ratio of 2.95, a current ratio of 3.09 and a debt-to-equity ratio of 0.38.

GeneDx (NASDAQ:WGS) last issued its earnings results on Monday, May 4th. The company reported ($0.28) earnings per share for the quarter, missing the consensus estimate of ($0.06) by ($0.22). GeneDx had a positive return on equity of 9.15% and a negative net margin of 17.58%.The company had revenue of $102.25 million for the quarter, compared to analyst estimates of $112.46 million. During the same quarter in the previous year, the company posted ($0.23) earnings per share. Equities research analysts expect that GeneDx Holdings Corp. will post -1 EPS for the current year.

Key Headlines Impacting GeneDx

Here are the key news stories impacting GeneDx this week:

• Negative Sentiment: A federal securities class action has been filed alleging GeneDx made false and misleading statements, including claims tied to its Fabric Genomics acquisition and its impact on the company’s business and prospects. Article Title
• Negative Sentiment: Multiple law firms are now soliciting investors and advertising lead-plaintiff deadlines, signaling rising legal overhang and potential additional distraction/costs for the company. Article Title
• Neutral Sentiment: Several firms are reminding investors that the deadline to seek lead-plaintiff status in the GeneDx class action is August 3, 2026; this is mainly procedural but keeps the controversy in focus. Article Title
• Neutral Sentiment: Commentary from plaintiff firms continues to highlight the prior Q1 2026 earnings miss, the steep stock drop, and the guidance cut as evidence supporting the lawsuit, reinforcing already negative investor sentiment. Article Title
• Negative Sentiment: The lawsuit and related notices may keep investors focused on GeneDx’s earlier operational disappointment, including the revenue miss and widened losses, which remain a headwind for the stock. Article Title

Insiders Place Their Bets

In other GeneDx news, CEO Katherine Stueland sold 46,933 shares of the company’s stock in a transaction dated Thursday, March 26th. The shares were sold at an average price of $63.17, for a total transaction of $2,964,757.61. Following the transaction, the chief executive officer directly owned 91,514 shares in the company, valued at approximately $5,780,939.38. This represents a 33.90% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Casdin Capital, Llc bought 185,000 shares of the stock in a transaction on Tuesday, May 19th. The shares were bought at an average price of $42.60 per share, for a total transaction of $7,881,000.00. Following the completion of the transaction, the director directly owned 3,367,164 shares of the company’s stock, valued at $143,441,186.40. This trade represents a 5.81% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Over the last three months, insiders have purchased 2,056,420 shares of company stock worth $82,035,340 and have sold 72,382 shares worth $4,889,473. 29.60% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

WGS has been the subject of several recent research reports. Zacks Research downgraded shares of GeneDx from a “strong-buy” rating to a “hold” rating in a research note on Friday, April 24th. Jefferies Financial Group set a $150.00 target price on shares of GeneDx in a research note on Monday, February 23rd. BTIG Research cut their price target on shares of GeneDx from $170.00 to $90.00 and set a “buy” rating for the company in a report on Tuesday, May 5th. Wells Fargo & Company reissued an “overweight” rating and set a $75.00 price target (down from $155.00) on shares of GeneDx in a report on Tuesday, May 5th. Finally, Piper Sandler reissued an “overweight” rating and set a $130.00 price target (down from $160.00) on shares of GeneDx in a report on Tuesday, February 24th. Six investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $96.43.

About GeneDx

GeneDx is a clinical diagnostics company specializing in comprehensive genetic and genomic testing for rare and inherited disorders. The company offers a broad portfolio of assays, including targeted gene panels, whole exome sequencing, whole genome sequencing and chromosomal microarray analysis. GeneDx’s laboratory services support the diagnosis of a wide range of conditions—from rare pediatric diseases and hereditary cancer syndromes to neuromuscular and metabolic disorders—by providing clinicians with detailed variant interpretation and reporting.

Founded in 2000 and based in Gaithersburg, Maryland, GeneDx was established with the aim of accelerating the translation of genomic discoveries into clinical care.